intracranial hemorrhage pipeline insight

DelveInsight’s, “Intracranial Hemorrhage - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Intracranial Hemorrhage pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Intracranial Hemorrhage: Understanding

Intracranial Hemorrhage: Overview

Intracranial hemorrhage encompasses four broad types of hemorrhage: epidural hemorrhage, subdural hemorrhage, subarachnoid hemorrhage, and intraparenchymal hemorrhage. Each type of hemorrhage is different concerning etiology, findings, prognosis, and outcome. Epidural hematoma is a collection of blood between the skull and the dura mater, the outermost protective membrane covering the brain. It can be arterial or venous in origin. Arterial epidural hematoma occurs after blunt trauma to the head, typically the temporal region, and is caused by a skull fracture that damages the middle meningeal artery. Venous epidural hematoma occurs when there is a skull fracture, and the venous bleeding from the skull fracture fills the epidural space. Subdural hematoma is bleeding into the subdural space, which is anatomically the arachnoid space. It occurs after a vessel traversing between the brain and skull is stretched, broken, or torn and begins to bleed into the subdural space. Subarachnoid hemorrhage is bleeding into the subarachnoid space. It can be traumatic or non-traumatic. Traumatic subarachnoid hemorrhage occurs after a blunt head injury with or without penetrating trauma or sudden acceleration changes to the head. Non-traumatic subarachnoid hemorrhage is bleeding into the subarachnoid space without identifiable aneurysms. Intraparenchymal hemorrhage is bleeding into the brain parenchyma proper and can be caused by hypertension, arteriovenous malformation, amyloid angiopathy, aneurysm rupture, tumor, coagulopathy, infection, vasculitis, and trauma.

 

Intracranial hemorrhage, a critical condition characterized by bleeding within the brain, is diagnosed through a comprehensive evaluation that considers symptoms, medical history, medications, and family history. Diagnostic tests such as CT scans and laboratory studies like complete blood count and coagulation studies play a vital role in identifying the source of bleeding and assessing the patient's condition. Treatment approaches vary depending on the severity of the hemorrhage and may involve medical management to control blood pressure, reversal of anticoagulation, or surgical interventions to remove clots and alleviate pressure on the brain. The prognosis is influenced by factors such as the size of the hemorrhage, timeliness of treatment, and the patient's overall health status. Early diagnosis and appropriate management are crucial for optimizing outcomes in patients with intracranial hemorrhage.

 

Treatment for intracranial hemorrhage involves stopping the bleeding, removing the clot, and relieving pressure on the brain. Medical management may include controlling blood pressure, reversing anticoagulation, and administering anticonvulsants for seizure activity. Surgical interventions such as craniotomy, stereotactic aspiration, or endoscopic evacuation may be necessary for certain cases. The prognosis depends on factors like the size of the hemorrhage, promptness of treatment, and the patient's overall health status. Early diagnosis and appropriate management are crucial for optimizing outcomes in patients with intracranial hemorrhage.

 

"Intracranial Hemorrhage- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Intracranial Hemorrhage pipeline landscape is provided which includes the disease overview and Intracranial Hemorrhage treatment guidelines. The assessment part of the report embraces, in depth Intracranial Hemorrhage commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Intracranial Hemorrhage collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Intracranial Hemorrhage R&D. The therapies under development are focused on novel approaches to treat/improve Intracranial Hemorrhage.

Intracranial Hemorrhage Emerging Drugs Chapters

This segment of the Intracranial Hemorrhage report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Intracranial Hemorrhage Emerging Drugs

 

GTX 104: Acasti Pharma

GTX-104 is a clinical stage, novel nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine. This nimodipine injectable formulation is comprised of a nimodipine base, an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection. GTX-104 is an aqueous solution substantially free of organic solvents, such that the nimodipine is contained in a concentrated injection solution, suspension, emulsion or complex as a micelle, a colloidal particle or an inclusion complex, and the formulation is stable and clear. Currently, the drug is in Phase III stage of clinical trial for the treatment of intracranial hemorrhage.

 

OKL-1111: Alveron Pharma

OKL-1111 is a procoagulant cyclodextrin derivative being developed by Alveron Pharma as a rapid, first-line therapy for haemorrhagic stroke or intracranial haemorrhage (ICH). It is being developed as a ready-to-use solution for injection, eliminating the time-consuming preparation step required for current therapies. The drug has a universal mode of action, not requiring the identification of the anticoagulant, and is being positioned as a potential breakthrough in the treatment of haemorrhagic stroke, a severe unmet medical need. OKL-1111 has demonstrated the ability to reverse the anticoagulant effects of various anticoagulants and platelet inhibitors in vitro and in vivo, including direct oral anticoagulants, vitamin K antagonists, low molecular weight heparinoids, and platelet inhibitors. Currently the drug is in Phase I stage of its clinical trial.

Further product details are provided in the report……..

Intracranial Hemorrhage: Therapeutic Assessment

This segment of the report provides insights about the different Intracranial Hemorrhage drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Intracranial Hemorrhage

There are approx. 8+ key companies which are developing the therapies for Intracranial Hemorrhage. The companies which have their Intracranial Hemorrhage drug candidates in the most advanced stage, i.e. Phase III include, Acasti Pharma.

 

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Intracranial Hemorrhage pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Intracranial Hemorrhage: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Intracranial Hemorrhage therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Intracranial Hemorrhage drugs.

Intracranial Hemorrhage Report Insights

• Intracranial Hemorrhage Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Intracranial Hemorrhage Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Intracranial Hemorrhage drugs?
• How many Intracranial Hemorrhage drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Intracranial Hemorrhage?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Intracranial Hemorrhage therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Intracranial Hemorrhage and their status?
• What are the key designations that have been granted to the emerging drugs?